HDAC Cancer Research Results

HDAC, Histone deacetylases: Click to Expand ⟱
Source:
Type:
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped.
-Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation.
-HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer.
-HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells.
-HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis.
-HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type.
-While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes.
-HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases.
-HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
5732- Buty,    GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
- Study, CRC, NA
HCAR2↑, other↓, Apoptosis↑, HDAC↓, Bcl-2↓, Bcl-xL↓, cycD1/CCND1↓, DR5↑, NF-kB↓, GutMicro↑, SLC12A5↝,
5731- Buty,    The Warburg Effect Dictates the Mechanism of Butyrate Mediated Histone Acetylation and Cell Proliferation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, Warburg↓, TumCP⇅, HATs↑, BioAv↓, other↝, Risk↓,
5737- Buty,    Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming
- in-vitro, CRC, HCT116
HDAC↓, TumCP↓, PKM2↑, Warburg↓,
2047- Buty,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24/HTB-9 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
1080- Buty,    Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition
- in-vitro, CRC, HT-29
HDAC↓, TNF-α↓, COX2↓,
3230- EGCG,    Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, DNMTs↓,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Casp3↑, Casp7↑, HDAC↓,
2915- LT,    Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells
- in-vitro, Colon, HT29 - in-vitro, CRC, SNU-407 - in-vitro, Nor, FHC
DNMTs↓, TET1↑, NRF2↑, HDAC↓, tumCV↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, ROS↓, GSS↑, Catalase↑, HO-1↑, DNMT1↓, DNMT3A↓, TET1↑, TET3↑, TET2↓, P53↑, P21↑,
2075- PB,  Chemo,    Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
- Trial, CRC, NA
OS↑, HDAC↓,
2040- SAHA,    The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
- in-vitro, Pca, LNCaP - in-vitro, CRC, T24/HTB-9 - in-vitro, BC, MCF-7
HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,
1500- SFN,    A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase
- in-vitro, Nor, HEK293 - in-vitro, CRC, HCT116
HDAC↓, P21↑, TOPflash↑,
1496- SFN,  VitD3,    Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells
- in-vitro, CRC, Caco-2
eff↑, VDR↑, CYP11A1↓, HDAC↓,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   GSS↑, 1,   HO-1↑, 1,   NRF2↑, 1,   PARK2↑, 1,   ROS↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   PKM2↑, 1,   Warburg↓, 2,  

Cell Death ⓘ

Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp9↑, 1,   DR5↑, 1,  

Kinase & Signal Transduction ⓘ

HCAR2↑, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   other↓, 1,   other↝, 1,   TET3↑, 1,   tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 2,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

BMI1↓, 1,   Diff↑, 1,   HDAC↓, 12,   mTOR↑, 1,   TOPflash↑, 1,   TumCG↓, 2,   VDR↑, 1,  

Migration ⓘ

E-cadherin↑, 1,   miR-139-5p↑, 1,   N-cadherin↓, 1,   Snail↓, 1,   TET1↑, 2,   TumCI?, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumCP⇅, 1,   TumMeta↓, 1,   TXNIP↑, 1,   Vim↓, 1,  

Barriers & Transport ⓘ

SLC12A5↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   HCAR2↑, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CYP11A1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↓, 1,   eff↑, 1,   TET2↓, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 1,   Risk↓, 1,  
Total Targets: 70

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HDAC, Histone deacetylases
5 Butyrate
2 Luteolin
2 Sulforaphane (mainly Broccoli)
1 EGCG (Epigallocatechin Gallate)
1 Cisplatin
1 Phenylbutyrate
1 Chemotherapy
1 Vorinostat
1 Vitamin D3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:140  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page